EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Near-Infrared Photoimmunotherapy in Brain Tumors—An Unexplored Frontier

Haruka Yamaguchi iD, Masayasu Okada iD, Takuya Otani, Jotaro On iD, Satoshi Shibuma, Toru Takino, Jun Watanabe iD, Yoshihiro Tsukamoto iD, Ryosuke Ogura iD, Makoto Oishi, Takamasa Suzuki, Akihiro Ishikawa und 2 weitere

Pharmaceuticals · 19.05.2025 · 18 (5) · 751

DOI: 10.3390/ph18050751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.05.2025. Verfasst von Haruka Yamaguchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Life Dentistry at Niigata, The Nippon Dental University, Niigata 951-8580, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Society for Promotion of Science KAKENHI, New Sustainable Growth (NSG) group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer treatment that uses near-infrared light to activate a conjugate of a monoclonal antibody (mAb) and a photoactivatable silica phthalocyanine dye (IRDye700DX: IR700). Unlike conventional photodynamic therapy (PDT), NIR-PIT selectively destroys targeted tumor cells while preserving the surrounding normal tissue and providing superior tissue penetration. Recently, NIR-PIT has been approved for the treatment of unresectable recurrent head and neck cancers in Japan. It induces highly selective cancer cell death; therefore, it is expected to be a new curative treatment option for various cancers, including brain tumors. In this review, we compare the principles of NIR-PIT and PDT and discuss the potential applications of NIR-PIT for brain tumors. We selected targetable proteins across various types of brain tumors and devised a strategy to effectively pass the mAb–IR700 conjugate through the blood–brain barrier (BBB), which is a significant challenge for NIR-PIT in treating brain tumors. Innovative approaches for delivering the mAb–IR700 conjugate across the BBB include exosomes, nanoparticle-based systems, and cell-penetrating peptides. Small-molecule compounds, such as affibodies, are anticipated to rapidly accumulate in tumors within intracranial models, and our preliminary experiments demonstrated rapid uptake. NIR-PIT also induces immunogenic cell death and activates the anti-tumor immune response. Overall, NIR-PIT is a promising approach for treating brain tumors. It has the potential to overcome the limitations of conventional therapies and offers new hope to patients with brain tumors.

Schlagwörter

Stichwörter der Autor:innen

IR700brain metastasisbrain tumorscentral nervous systemgliomaintraoperative treatmentlasermeningiomanear-infrared photoimmunotherapyphotodynamic therapy

Autor:innen und Institutionen

  • Department of Biochemistry, School of Life Dentistry at Niigata, The Nippon Dental University, Niigata 951-8580, Japan.
  • Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
  • Department of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
  • Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
  • Faculty of Engineering, Niigata University, Niigata 950-2181, Japan.
  • Startup Incubation Center, Shimadzu Corporation, Kyoto 604-8511, Japan.

ORCID-Profile: Haruka Yamaguchi, Masayasu Okada, Jotaro On, Jun Watanabe, Yoshihiro Tsukamoto, Ryosuke Ogura, Manabu Natsumeda

Förderung

  • Japan Society for the Promotion of Science
  • Japan Society for Promotion of Science KAKENHI
  • New Sustainable Growth (NSG) group

Zitieren

APA

Yamaguchi, H., Okada, M., Otani, T., On, J., Shibuma, S., Takino, T., Watanabe, J., Tsukamoto, Y., Ogura, R., Oishi, M., Suzuki, T., Ishikawa, A., Sakata, H., & Natsumeda, M. (2025). Near-Infrared Photoimmunotherapy in Brain Tumors—An Unexplored Frontier. Pharmaceuticals, 18(5), 751. https://doi.org/10.3390/ph18050751

Vancouver

Yamaguchi H, Okada M, Otani T, On J, Shibuma S, Takino T, et al. Near-Infrared Photoimmunotherapy in Brain Tumors—An Unexplored Frontier. Pharmaceuticals. 2025;18(5):751. doi:10.3390/ph18050751

BibTeX
@article{Yamaguchi2025,
  author = {Yamaguchi, Haruka and Okada, Masayasu and Otani, Takuya and On, Jotaro and Shibuma, Satoshi and Takino, Toru and Watanabe, Jun and Tsukamoto, Yoshihiro and Ogura, Ryosuke and Oishi, Makoto and Suzuki, Takamasa and Ishikawa, Akihiro and Sakata, Hideyuki and Natsumeda, Manabu},
  title = {Near-Infrared Photoimmunotherapy in Brain Tumors—An Unexplored Frontier},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {5},
  pages = {751},
  doi = {10.3390/ph18050751}
}
Kostenlos starten →